EIT Pharma raised $35 million in Series A financing to support FDA review, manufacturing preparation, commercial readiness, and its infectious disease pipeline.
- Amount
- $35M
- Stage
- Series A
- Announced
- 31 August 2026
- Lead
- Propel Bio Partners
- Other investors
- Good Ventures, Arrowtown
- Use of funds
- Continued FDA review of lonafarnib, future manufacturing and commercial readiness, pipeline advancement and general corporate operations.
- Checked
- Announced by the company